Kyverna Therapeutics, Inc.
KYTX
$7.18
$0.629.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 30.46M | 35.82M | 37.43M | 33.48M | 29.19M |
| Gross Profit | -30.46M | -35.82M | -37.43M | -33.48M | -29.19M |
| SG&A Expenses | 8.27M | 8.59M | 9.98M | 10.36M | 9.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.73M | 44.41M | 47.41M | 43.84M | 38.77M |
| Operating Income | -38.73M | -44.41M | -47.41M | -43.84M | -38.77M |
| Income Before Tax | -36.79M | -42.08M | -44.64M | -37.49M | -34.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.79M | -42.08M | -44.64M | -37.49M | -34.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.79M | -42.08M | -44.64M | -37.49M | -34.49M |
| EBIT | -38.73M | -44.41M | -47.41M | -43.84M | -38.77M |
| EBITDA | -38.47M | -44.37M | -46.91M | -43.52M | -38.45M |
| EPS Basic | -0.85 | -0.97 | -1.03 | -0.87 | -0.80 |
| Normalized Basic EPS | -0.53 | -0.61 | -0.65 | -0.58 | -0.50 |
| EPS Diluted | -0.85 | -0.97 | -1.03 | -0.87 | -0.80 |
| Normalized Diluted EPS | -0.53 | -0.61 | -0.65 | -0.58 | -0.50 |
| Average Basic Shares Outstanding | 43.42M | 43.23M | 43.22M | 43.23M | 43.16M |
| Average Diluted Shares Outstanding | 43.42M | 43.23M | 43.22M | 43.23M | 43.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |